Serum sclerostin and sympathetic skin response: relationship with myeloma bone disease

Table 5 Multivariate analyses between different risk factors and advanced myeloma bone disease (MBD- grade 3) in multiple myeloma patients (group II)

Variables	MBD (35)		OR [95% CI]	p value
Variables	Advanced (20)	Not advanced (15)	OR [95% CI]	p value
Sex
Females (16)	9	7	5.5 [0.2–8.7]	0.5
Males (19)	11	8	5.5 [0.2–8.7]	0.5
Age at diagnosis
> 60 years (14)	8	6	3.9 [0.12–8.97]	0.6
≤ 60 years (21)	12	9	3.9 [0.12–8.97]	0.6
ISS stages
3 (22)	13	9	9.9 [10.2–13.3]	0.03*
1 and 2 (13)	7	6	9.9 [10.2–13.3]	0.03*
LDH
Elevated (23)	15	8	6.1 [11.2–13.3]	0.01*
Not elevated (12)	5	7	6.1 [11.2–13.3]	0.01*
SSR
Undetectable (15)	14	1	5.5 [11.9–22.1]	0.02*
Detectable (20)	6	14	5.5 [11.9–22.1]	0.02*
Serum sclerostin
≥ 0.40 ng/ml (23)	18	5	5.9 [13.9–14.67]	0.04*
< 0.40 ng/ml (12)	2	10	5.9 [13.9–14.67]	0.04*

OR odds ratio, CI confidence interval, ISS International Staging System, MBD myeloma bone disease, SSR sympathetic skin response, LDH lactate dehydrogenase
*Significant